Literature DB >> 680419

Perhexiline maleate-induced hepatitis.

P Paliard, D Vitrey, G Fournier, J Belhadjali, L Patricot, F Berger.   

Abstract

5 patients treated with perhexiline maleate, 200-400 mg/day for at least 6 months, exhibited evidence of hepatitis. The picture was very similar to acute alcoholic hepatitis, clinically, biologically and histologically with presence of necrosis, Mallory's hyaline, polynuclear infiltration and to a lesser degree, steatosis. Association with peripheral neuropathy, hypoglycemia, and renal failure appears strikingly frequently. The evolution was severe since 3 patients died within 6 months, even after treatment withdrawal. Further studies are to be done to understand the mechanisms of hepatic and neurologic toxicity, and to measure the hazards of this drug. These studies could bring a new insight to alcohol toxicity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 680419     DOI: 10.1159/000198145

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

1.  Effects of Pexid on liver cell cultures. Ultrastructural and histoenzymological studies.

Authors:  A Lageron; J Scotto; M Gautier
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

2.  Mitochondrial dysfunction and apoptosis underlie the hepatotoxicity of perhexiline.

Authors:  Zhen Ren; Si Chen; Ji-Eun Seo; Xiaoqing Guo; Dongying Li; Baitang Ning; Lei Guo
Journal:  Toxicol In Vitro       Date:  2020-08-28       Impact factor: 3.500

3.  Perhexiline maleate toxicity on human liver cell lines.

Authors:  J Y Le Gall; A Guillouzo; D Glaise; Y Deugnier; M Messner; M Bourel
Journal:  Gut       Date:  1980-11       Impact factor: 23.059

Review 4.  Drug-induced cholestasis.

Authors:  H J Zimmerman; J H Lewis
Journal:  Med Toxicol       Date:  1987 Mar-Apr

5.  Polymorphic hydroxylation of perhexiline in vitro.

Authors:  L B Sørensen; R N Sørensen; J O Miners; A A Somogyi; N Grgurinovich; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

6.  Impaired oxidation of debrisoquine in patients with perhexiline liver injury.

Authors:  M Y Morgan; R Reshef; R R Shah; N S Oates; R L Smith; S Sherlock
Journal:  Gut       Date:  1984-10       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.